Posted on 3 月 27, 20243/27/24
Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur
Posted on 10 月 17, 202310/17/23
Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)
Posted on 8 月 1, 20238/1/23
Commercial Key Success Factors (KSFs) for Global Drug Development Programs
Posted on 4 月 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 10 月 12, 202210/12/22
The Evolution of HTA and Its Impact on Drug Prices in Japan
Posted on 4 月 14, 20224/14/22
Impact of Patient Reported Outcome Measures on HTA Decisions for Rare Diseases
Posted on 4 月 1, 20224/1/22
What You Need to Know as the European Union Embarks on Joint Health Technology Assessment (HTA)
Posted on 12 月 21, 202112/21/21
Launch Sequencing and Market Prioritization in an Evolving Global Market
Posted on 12 月 6, 202112/6/21